Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SADIE2: Empagliflozin for Adipose Inflammation in Obesity
NCT05972564Phase 2Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in obesity, metabolic syndrome, sponsored by Vanderbilt University Medical Center. Started Sep 2023; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
obesitymetabolic syndrome
Beyond the preview
Go deeper on NCT05972564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972564.